The H4C1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, designed for the targeted disruption of the H4C1 gene. This gene encodes histone H4, a fundamental core component of the nucleosome. The polyclonal format represents a genetically heterogeneous population of cells carrying diverse CRISPR/Cas9-mediated disruptions of H4C1, providing a robust loss-of-function model without isolation of single-cell clones. The pooled nature of this product avoids clonal artifacts and allows the study of gene perturbation across a mixed genetic background, making it suitable for high-throughput screening and functional genomics applications.
HeLa cells are an immortalized human epithelial cell line isolated from a cervical adenocarcinoma of a 31-year-old female. They contain integrated human papillomavirus 18 (HPV18) DNA and exhibit an aneuploid, hypertriploid karyotype. As one of the most widely utilized continuous cell lines in biomedical research, HeLa cells serve as a versatile model for investigating epithelial cancer biology, cell cycle regulation, apoptosis, and intracellular signaling. Their robust proliferation and ease of manipulation make them an ideal host for genetic perturbation experiments, particularly in the context of chromatin biology where the interplay between viral oncoproteins and host epigenetic machinery can be dissected.
Histone H4, encoded by H4C1, is a highly conserved structural protein central to chromatin architecture. Together with histones H2A, H2B, and H3, it forms the histone octamer around which DNA is wrapped to constitute the nucleosome core particle. H4C1 is essential for DNA packaging, nucleosome assembly, and the regulation of gene expression through post-translational modifications. Its expression is tightly controlled by cell cycle-dependent mechanisms; upstream regulators include E2F transcription factors, NPAT, and the Cyclin E/CDK2 complex, which coordinate histone synthesis during S phase. H4C1 interacts directly with histone chaperones such as CAF-1, ASF1, and NAP1, and is integrated into chromatin remodeling complexes. Downstream, H4C1 influences global transcription, DNA replication fidelity, DNA repair pathways, and chromosome segregation, all of which rely on proper nucleosome stability and dynamics.
In HeLa cells, disruption of H4C1 provides a powerful tool to examine the consequences of histone H4 deficiency within a cancer cell context. The presence of HPV18 oncoproteins, which modulate host chromatin and cell cycle machinery, offers a unique backdrop for studying synthetic interactions and vulnerabilities. Loss of H4C1 can lead to nucleosome depletion, disrupted chromatin higher-order structure, and consequent genomic instability, thereby recapitulating aspects of aberrant chromatin remodeling disorders. This model allows researchers to probe how histone dosage affects oncogenic transcription programs, DNA damage responses, and proliferation in a transformation-competent cellular environment, shedding light on the potential role of histone imbalances in tumorigenesis.
This polyclonal knockout cell population is ideally suited for a range of experimental applications, including chromatin dynamics studies, epigenetic profiling, and functional analysis of histone variants. Representative assays include western blotting to assess histone H4 protein levels, chromatin immunoprecipitation (ChIP) for histone modifications, cell cycle analysis by flow cytometry, RT-qPCR of histone mRNA, immunofluorescence for chromatin structure visualization, RNA-seq to evaluate global transcriptional changes, and viability/apoptosis assays to measure cellular fitness. Researchers can leverage this model to investigate epigenetic regulation in cancer, explore cell cycle-dependent histone synthesis, and develop or validate histone-targeted therapeutic strategies. For detailed technical specifications and support, please contact Ascent Research.
